2seventy Bio Analyst Ratings
2seventy Bio Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/20/2023 | 12.99% | Wedbush | → $2 | Downgrades | Outperform → Neutral |
| 10/30/2023 | — | Leerink Partners | Downgrades | Outperform → Market Perform | |
| 10/12/2023 | 634.46% | Citigroup | → $13 | Initiates Coverage On | → Buy |
| 09/13/2023 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 09/13/2023 | 182.49% | Goldman Sachs | → $5 | Downgrades | Buy → Neutral |
| 09/12/2023 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 08/15/2023 | 1368.93% | Guggenheim | $27 → $26 | Maintains | Buy |
| 08/15/2023 | 1255.93% | Goldman Sachs | $27 → $24 | Maintains | Buy |
| 07/28/2023 | 1142.94% | Wedbush | $26 → $22 | Maintains | Outperform |
| 07/28/2023 | 634.46% | Morgan Stanley | $25 → $13 | Downgrades | Overweight → Equal-Weight |
| 07/20/2023 | 1312.43% | Morgan Stanley | $28 → $25 | Maintains | Overweight |
| 05/18/2023 | 1368.93% | Wedbush | → $26 | Reiterates | Outperform → Outperform |
| 05/15/2023 | 1368.93% | Wedbush | → $26 | Reiterates | Outperform → Outperform |
| 03/17/2023 | 1086.44% | Wedbush | $28 → $21 | Maintains | Outperform |
| 01/24/2023 | 1481.92% | Morgan Stanley | $29 → $28 | Maintains | Overweight |
| 01/20/2023 | 1481.92% | Goldman Sachs | $25 → $28 | Maintains | Buy |
| 01/10/2023 | 1820.9% | SVB Leerink | $41 → $34 | Maintains | Outperform |
| 11/08/2022 | 1538.42% | Morgan Stanley | $27 → $29 | Maintains | Overweight |
| 11/08/2022 | 2216.38% | SVB Leerink | $42 → $41 | Maintains | Outperform |
| 10/31/2022 | 1594.92% | Guggenheim | → $30 | Initiates Coverage On | → Buy |
| 08/15/2022 | 1425.42% | Morgan Stanley | $28 → $27 | Maintains | Overweight |
| 07/15/2022 | 1481.92% | Morgan Stanley | $31 → $28 | Maintains | Overweight |
| 05/17/2022 | 1651.41% | Morgan Stanley | $36 → $31 | Maintains | Overweight |
| 05/02/2022 | 1368.93% | Goldman Sachs | → $26 | Initiates Coverage On | → Buy |
| 02/10/2022 | 2046.89% | SVB Leerink | → $38 | Initiates Coverage On | → Outperform |
| 01/06/2022 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 11/08/2021 | 3967.8% | Morgan Stanley | → $72 | Initiates Coverage On | → Overweight |
| 11/08/2021 | 2159.89% | Wedbush | → $40 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/20/2023 | 12.99% | Wedbush | → 2 美元 | 降級 | 跑贏大盤 → 中性 |
| 10/30/2023 | — | Leerink 合作伙伴 | 降級 | 跑贏大盤 → 市場表現 | |
| 2023 年 12 月 10 日 | 634.46% | 花旗集團 | → 13 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 09/13/2023 | — | 古根海姆 | 降級 | 買入 → 中性 | |
| 09/13/2023 | 182.49% | 高盛 | → 5 美元 | 降級 | 買入 → 中性 |
| 09/12/2023 | — | 古根海姆 | 降級 | 買入 → 中性 | |
| 08/15/2023 | 1368.93% | 古根海姆 | 27 美元 → 26 美元 | 維護 | 買 |
| 08/15/2023 | 1255.93% | 高盛 | 27 美元 → 24 美元 | 維護 | 買 |
| 07/28/2023 | 1142.94% | Wedbush | 26 美元 → 22 美元 | 維護 | 跑贏大盤 |
| 07/28/2023 | 634.46% | 摩根士丹利 | 25 美元 → 13 美元 | 降級 | 超重 → 重量相等 |
| 07/20/2023 | 1312.43% | 摩根士丹利 | 28 美元 → 25 美元 | 維護 | 超重 |
| 05/18/2023 | 1368.93% | Wedbush | → 26 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
| 05/15/2023 | 1368.93% | Wedbush | → 26 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
| 03/17/2023 | 1086.44% | Wedbush | 28 美元 → 21 美元 | 維護 | 跑贏大盤 |
| 01/24/2023 | 1481.92% | 摩根士丹利 | 29 美元 → 28 美元 | 維護 | 超重 |
| 01/20/2023 | 1481.92% | 高盛 | 25 美元 → 28 美元 | 維護 | 買 |
| 01/10/2023 | 1820.9% | SVB Leerink | 41 美元 → 34 美元 | 維護 | 跑贏大盤 |
| 2022 年 8 月 11 日 | 1538.42% | 摩根士丹利 | 27 美元 → 29 美元 | 維護 | 超重 |
| 2022 年 8 月 11 日 | 2216.38% | SVB Leerink | 42 美元 → 41 美元 | 維護 | 跑贏大盤 |
| 10/31/2022 | 1594.92% | 古根海姆 | → 30 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/15/2022 | 1425.42% | 摩根士丹利 | 28 美元 → 27 美元 | 維護 | 超重 |
| 07/15/2022 | 1481.92% | 摩根士丹利 | 31 美元 → 28 美元 | 維護 | 超重 |
| 05/17/2022 | 1651.41% | 摩根士丹利 | 36 美元 → 31 美元 | 維護 | 超重 |
| 05/02/2022 | 1368.93% | 高盛 | → 26 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 02/10/2022 | 2046.89% | SVB Leerink | → 38 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 01/06/2022 | — | Cowen & Co. | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 2021 年 8 月 11 日 | 3967.8% | 摩根士丹利 | → 72 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 2021 年 8 月 11 日 | 2159.89% | Wedbush | → 40 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
What is the target price for 2seventy bio (TSVT)?
27eventy bio (TSVT) 的目標價格是多少？
The latest price target for 2seventy bio (NASDAQ: TSVT) was reported by Wedbush on November 20, 2023. The analyst firm set a price target for $2.00 expecting TSVT to rise to within 12 months (a possible 12.99% upside). 17 analyst firms have reported ratings in the last year.
Wedbush於2023年11月20日公佈了2seventy bio（納斯達克股票代碼：TSVT）的最新目標股價。該分析公司將目標股價定爲2.00美元，預計TSVT將在12個月內升至12個月內（可能上漲12.99％）。去年有17家分析公司公佈了評級。
What is the most recent analyst rating for 2seventy bio (TSVT)?
分析師對27eventy bio（TSVT）的最新評級是多少？
The latest analyst rating for 2seventy bio (NASDAQ: TSVT) was provided by Wedbush, and 2seventy bio downgraded their neutral rating.
Wedbush提供了2seventy bio（納斯達克股票代碼：TSVT）的最新分析師評級，2seventy bio下調了中性評級。
When is the next analyst rating going to be posted or updated for 2seventy bio (TSVT)?
27eventy bio（TSVT）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 2seventy bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 2seventy bio was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與2seventy bio的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。2seventy bio的最後一次評級是在2023年11月20日提交的，因此您應該預計下一個評級將在2024年11月20日左右公佈。
Is the Analyst Rating 2seventy bio (TSVT) correct?
分析師評級 270ty bio (TSVT) 正確嗎？
While ratings are subjective and will change, the latest 2seventy bio (TSVT) rating was a downgraded with a price target of $0.00 to $2.00. The current price 2seventy bio (TSVT) is trading at is $1.77, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的2seventy bio（TSVT）評級已下調，目標股價爲0.00美元至2.00美元。目前2seventy bio（TSVT）的交易價格爲1.77美元，在分析師的預測區間內。